Sub-minimum inhibitory concentrations of biocides induced biofilm formation in *Pseudomonas aeruginosa*

S. Hemati^{1,2}, E. Kouhsari³, N. Sadeghifard¹, A. Maleki¹, N. Omidi^{1,2}, Z. Mahdavi^{1,2} and I. Pakzad^{1,2}

1) Clinical Microbiology Research Centre, 2) Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam and 3) Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Abstract

It is clear that biofilm formation causes many serious health-care problems. Interestingly, sub minimum inhibitory concentrations (sub-MICs) of some biocides can induce biofilm formation in bacteria. We investigated whether sub-MICs of Savlon, chlorhexidine and deconex®, as biocidal products, can induce biofilm formation in clinical isolates of *Pseudomonas aeruginosa*. To determine MICs and biofilm formation, we performed microtitre plate assays. All three biocides induced biofilm formation at sub-MICs; Savlon was the most successful antiseptic agent to induce biofilm formation among *P. aeruginosa* isolates. Deconex had the best inhibition effect on planktonic cultures of *P. aeruginosa* isolates. We concluded that sub-MICs of Savlon and deconex could significantly induce biofilm formation. © 2020 The Authors. Published by Elsevier Ltd.

Keywords: Biofilm formation, Pseudomonas aeruginosa, sub-MIC, biocides Original Submission: 13 November 2019; Revised Submission: 14 October 2020; Accepted: 15 October 2020 Article published online: 19 October 2020

Corresponding author: I. Pakzad, Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran. E-mail: Pakzad_i2006@yahoo.com

Introduction

Antiseptics have been extensively applied in domestic and clinical settings as a convenient way of disinfection and protection against bacterial contamination for more than half a century [1]. *Pseudomonas aeruginosa*, a human opportunistic Gram-negative pathogen, is one of the most important nosocomial pathogens and is a major health problem, primarily in immunocompromised individuals. It causes a wide spectrum of infections in multiple organs, such as the respiratory, urinary and gastrointestinal tracts [2–4]. This organism is highly tolerant of harsh conditions and has the ability to survive in various environments, including hospital environments, on medical equipment, such as mechanical ventilators, urinary or dialysis catheters and endoscopes, and in sinks. Stability in these environments causes contamination [5]. Biofilm formation by P. aeruginosa increases morbidity and mortality through its protection against the host immune system and antibiotic treatment [6,7]. Bacterial biofilms are responsible for about 80% of all chronic human infections [8,9]. A biofilm comprises a complex aggregation of microorganisms surrounded by a matrix of extracellular polymeric substance [10], and is a mode of life that helps bacteria to resist antibiotics and survive [11]. Unfortunately, biofilm structures cause many problems through their formation on tissue and medically implanted devices [12]. Although most currently available antimicrobial agents cannot eradicate biofilm infections, some antimicrobial agents can induce their formation at sub-minimal inhibitory concentrations (sub-MICs) [13]. To eradicate the bacterial biofilm, a combination of multiple strategies to boost both activity of conventional antimicrobial agents and the host immune system is necessary [9,14]. Therefore, the aim of the study was to determine the in vitro effect of some conventional antiseptic agents, including Savlon, chlorhexidine and deconex® in biofilm formation by P. aeruginosa isolates.

Materials and methods

Ethics statement

Written informed consent was obtained from all patients and the study protocol was approved by the ethics committee of the llam University of Medical Sciences.

Bacterial isolates

This cross-sectional study was conducted from May 2015 to November 2016 in some of the hospitals in Ilam province, western Iran. Fifty clinical *P. aeruginosa* isolates (obtained from burn and urinary tract infections) were identified by standard conventional microbiological and biochemical methods [15].

Sub-MIC determination

Three biocidal agents were used. Chlorhexidine 0.2% (Iran Najo Pharmaceutical Co., Tehran, Iran) contains 0.2 g chlorhexidine per 100 mL and is recommended for use without dilution. Savlon (Behsa Pharmaceutical Co., Tehran, Iran) contains 1.5 g chlorhexidine gluconate plus 15 g cetrimide per 100 mL and is recommended for use at a 1:30 dilution. 100 g Deconex® (Borer Chemie AG, Zuchwil, Switzerland) contains 12 g ethanedial, 0.5 g pentanedial, 7.5 g didecyldimethylammonium chloride and is recommended for use at 1% and 2% dosages.

We investigated the MIC value of deconex in a total volume of 200 μ L using the microtitre method from the Hengzhuang *et al.* procedure [16]. In the case of chlorhexidine, the dilutions used were 1:600, 1:500, 1:400, 1:200, 1:100, 1:66 and 1:50. For Savlon, the dilutions used were 1:40 000, 1:16 000, 1:8000, 1:4000, 1:2640, 1:2000 and 1:1600. Finally, 1:60 000, 1:33 300, 1:20 000, 1:10 000, 1:6600, 1:500 and 1:400 were used for deconex.

Biofilm assay

We used the microtitre plates assay for biofilm assay in Luria-Bertani medium (Merck, Darmstadt, Germany) [17]. Briefly, we added appropriately adjusted overnight bacterial cultures (0.5 McFarland, including, 1.5 × 10⁸ CFU/mL) into the wells of 96-well plates (SPL, Gyeonggi-do, South Korea), followed by incubation at 37°C for 48 hours. After washing three times in phosphate-buffered saline, unattached bacterial cells were removed. Biofilm was stained with 200 µL crystal violet 0.1% (weight/volume) for 15 minutes and the wells were rewashed with phosphate-buffered saline (pH 7.2). The dye bound to the adherent cells was resolubilized with 200 µL of 95% ethanol. Optical density (OD) was measured at 492 nm using an ELISA reader (Synergy4; BioTek, Winooski, VT, USA). Each assay was performed in triplicate. Negative control wells were also included (uninoculated broth). Pseudomonas aeruginosa PAOI (a biofilm-producing isolate) was used as positive control [18].

The adherence capabilities of the test isolates were classified into four categories; three standard deviations (SDs) above the mean OD of the negative control (broth only) was considered as the cut-off optical density (ODc). Isolates were classified as follows: if OD \leq ODc, then the bacteria were non-adherent; if ODc < OD \leq 2 \times ODc, then the bacteria were weakly adherent; if 2 \times ODc < OD \leq 4 \times ODc, then the bacteria were moderately adherent; and if 4 \times ODc < OD, then the bacteria were strongly adherent.

In addition, for assaying the biofilm formation inducement, we used different concentrations of biocidal agents at sub-MICs in triplicate [19]. The biofilm value was estimated using the following formula: Biofilm value = (Test $OD_{492 nm}$ – Control $OD_{492 nm}$).

Statistical analysis

SPSS 19.0 software was used for statistical analysis (SPSS Inc., Armonk, NY, USA). Categorical variables were compared using the chi-squared test as appropriate. Student's *t*-test was used to compare the different biofilm categories. Values of p < 0.05 were considered as statistically significant.

Results

Our findings showed the high ability (86%) of biofilm formation in clinical *P. aeruginosa* isolates (Table 1). Interestingly, the ability of biofilm formation among isolates obtained from burn skin samples was higher than isolates obtained from urine samples (p 0.012). The results of the MIC assay showed that chlorhexidine had a MIC range from 1:400 to 1:50 (mean \approx 1:225). The MIC range was 1:33 300 to 1:100 (mean \approx 1:16 700) for deconex and Savlon had a MIC range from 1:400 to 1:8000 (mean \approx 1:2800).

Interestingly, the burn isolates were significantly more susceptible than the urinary tract infection isolates, especially they were more susceptible to chlorhexidine (Table 2). Notably, we observed that deconex had the best inhibition effect on planktonic cultures of *P. aeruginosa* isolates.

In within-group comparisons, based on the results shown in Table 3, proportions (95% Cl) of biofilm inducement in chlorhexidine, deconex and Savlon were 64% (49.2%–77.1%), 68% (53.3%–80.5%) and 76% (61.8%–86.9%), respectively. The binomial test showed that proportion of biofilm inducement in chlorhexidine was not significant, but in the deconex and Savlon groups, the proportion of biofilm inducement was significant (p 0.015 and p < 0.001, respectively) (Fig. 1). Between-group comparisons, as shown in Table 3, showed that the proportions of biofilm inducement in the deconex and Savlon

^{© 2020} The Authors. Published by Elsevier Ltd, NMNI, 38, 100794

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

groups were 6% and 19% more than chlorhexidine, but these differences were not significant (p 0.673 and p 0.190, respectively).

Discussion

In this study the effects of the commonly used antiseptics Savlon, chlorhexidine and deconex at sub-MICs on biofilm formation were determined using clinical P. aeruginosa isolates.

Several previous studies have demonstrated that biofilm formation can be induced by sub-MICs of antibacterial agents [20-22]. Biofilm formation is induced when bacteria are exposed to a sub-MIC of antimicrobial agents during chemotherapy, by varying gradients of antimicrobial agents over the course of the dosing regimen, or by bacterial location depth within the biofilm structure, which causes diffusion gradients [23]. We assessed whether the sub-MIC concentrations of antiseptic agents were able to induce biofilm formation. According to MIC data, we found that deconex was the best antiseptic agent against P. aeruginosa isolates (low concentration). Ogunniyi et al. [24] reported that MIC values of Savlon were in the high dilution range (low concentration) of 1:400

TABLE I. The results of biofilm formation in Pseudomonas aeruginosa

Biofilm production producer	Frequency	%
No biofilm producer	7	14.0
Weak biofilm producer	5	10.0
Moderate biofilm producer	14	28.0
Strong biofilm producer	24	48.0

and 1:350, whereas Enterobacter aerogenes needed a low dilution (1:50) for total growth inhibition.

Although deconex was the best antiseptic agent to remove pathogens from surfaces, it has been proved that this antiseptic agent is toxic and unstable [25]. These three antiseptic agents could induce biofilm formation at sub-MICs, and Savlon had more ability in biofilm induction. Increasing antibiotic resistance is one of the important problems related to biofilm formation [26]. Aka and Haji reported that the antibiotic concentration needed for eradicating the biofilm-forming bacteria is about 10 000 times greater than planktonic cells, and its formation can be induced by some factors or environmental conditions [22]. They investigated the effects of sub-MIC concentrations of antibiotics on the P. aeruginosa biofilm in the presence of chlorhexidine.

They also showed that P. aeruginosa isolates that are incubated in sub-inhibitory concentrations of chlorhexidine could induce stronger biofilms in the presence of sub-MICs of antibiotics. The outer membrane of P. aeruginosa is responsible for this resistance to chlorhexidine and many other antiseptics.

Lefebvre et al. [27] conducted a multistep strategy to generate a combined antibiofilm treatment (various commercial antiseptics, enzymes and EDTA) that could efficiently decrease the biomass of dense biofilms ($\geq 6 \times 10^7$ CFU/cm²) in P. aeruginosa and Staphylococcus aureus. The combination of antiseptics, EDTA and proteases, all at low concentrations, has shown a synergistic effect leading to total eradication of dense biofilms in both P. aeruginosa and S. aureus.

Their findings showed that bacterial biofilm was enhanced by chlorhexidine culture compared with chlorhexidine-free culture [22]. Moreover, a sub-MIC concentration of antimicrobial agents has a strong effect on mutation rates and horizontal antimicrobial resistance genes transfer [28].

TABLE 2. The MIC range of Savlon,	chlorhexidine and deconex®
-----------------------------------	----------------------------

Strain no. ^a	MIC range			Strain no.	MIC range				MIC range		
	Chlorhexidine	Deconex	Savlon		Chlorhexidine	Deconex	Savlon	Strain no.	Chlorhexidine	Deconex	Savlor
1	1:200	1:33 300	1:4000	18	1:400	1:33 300	1:8000	35	1:100	1:6600	1:1600
2	1:100	1:33 300	1:2000	19	1:200	1:10 000	I:2640	36	1:50	1:6600	1:1600
3	1:400	1:10 000	1:2640	20	1:200	1:10 000	1:4000	37	1:50	1:10 000	1:1600
4	1:200	1:400	1:4000	21	1:400	1:6600	1:1600	38	1:100	1:10 000	1:1600
5	1:100	1:6600	1:4000	22	1:200	1:10 000	1:4000	39	1:100	1:10 000	1:1600
6	1:200	1:33 300	1:2640	23	1:200	1:6600	1:2640	40	1:50	1:6600	1:1600
7	1:66	1:33 300	1:1600	24	1:200	1:10 000	1:4000	41	1:50	1:6600	1:1600
8	1:50	1:60 000	1:1600	25	1:200	1:10 000	1:4000	42	1:50	1:10 000	1:1600
9	1:200	1:60 000	1:2000	26	1:66	1:33 300	1:4000	43	1:50	1:10 000	1:4000
10	1:66	1:60 000	1:1600	27	1:200	1:10 000	1:4000	44	1:50	1:10 000	1:2000
ii .	1.200	1.60 000	1.1600	28	1.400	1.10 000	1.4000	45	1.50	1.6600	1.1600
12	1:100	1:6600	1:4000	29	1:100	1:60 000	1:2000	46	1:50	1:6600	1:1600
13	1.200	1.6600	1.4000	30	1.66	1.60 000	1.1600	47	1.50	1.10 000	1.4000
14	1:100	1:6600	1:4000	31	1:66	1:10 000	1:4000	48	1:400	1:500	1:2640
15	1.200	1.500	1.4000	32	1.66	1.6600	1.1600	49	1.100	1.10.000	1.4000
16	1.200	1.6600	1.2640	33	1:66	1.10.000	1.1600	50	1.50	1.60 000	1.4000
17	1.200	1.10 000	1.2640	34	1:66	1.6600	1.1600				

© 2020 The Authors. Published by Elsevier Ltd, NMNI, 38, 100794

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Biocides	Biofilm induceme	nt	Proportion% (95% CI)	p-value	Proportion ratio (95% CI)	p-value	
Chlorhexidine ($n = 50$)	Yes	32	64% (49.2–77.1) 36% (22.9–50.8)	0.065	Reference group	_	
deconex® ($n = 50$)	Yes	34	68% (53.3–80.5) 32% (19.5–46.7)	0.015	1.06 (0.80-1.40)	0.673	
Savlon ($n = 50$)	Yes No	38 12	76% (61.8–86.9) 24% (13.1–38.2)	<0.001	1.19 (0.92–1.54)	0.190	

TABLE 3. Proportion of biofilm inducement in chlorhexidine, deconex and Savlon group





The current study could be useful to optimize antiseptic concentrations. It is not necessary to use a higher than MIC concentration of antimicrobial agents for eradicating the bacterial pathogens. Ebrahimi *et al.* showed that benzalkonium chloride at concentrations higher than the MIC have no further effects on growth and biofilm formation of planktonic cells [29]. Currently, there is limited evidence about biofilm formation and its mechanism at sub-MICs of antimicrobial agents. A global response to cell stress (by directly or indirectly inducing the SOS response) seems to play an important role. However, the concentration of antimicrobial agent and the mechanisms involved are different for each bacterial species [23,30].

Our results displayed that they might be helpful to elaborate the efficient strategies in elimination of biofilms in *P. aeruginosa* and favour the healing process. However, the results here may have a potential clinical impact in the area of wound healing to eliminate the biofilm formation, such as local

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

disinfection in combination with antibiotics seems to be essential in the case of urinary or skin infections. Finally, it would be of interest to perform these tests routinely in case of persistence of these strains in case of relapse or of therapeutic failure.

Conclusions

The clinical isolates of *P. aeruginosa* in sub-MICs of chlorhexidine, Savlon and deconex exhibited induction of biofilm. Furthermore, deconex had a powerful inhibitory effect against *P. aeruginosa* isolates. However, there is little evidence about a mechanism at sub-MICs of antiseptics and the concentration of antiseptics; furthermore, the involved mechanisms differ for each bacterial species.

Conflict of interest

The authors declare that they have no competing interest.

Authors' contributions

SH and AM contributed to the conception and design of the work. ZM and NS contributed to the design of the work, and to final approval of the version to be published. EK contributed by drafting the work and revising it critically for important intellectual content. IP contributed in revising the article and final approval of the version to be published.

Funding

The work was financially supported by Ilam University of Medical Sciences for which we are very grateful.

Ethical approval

This project was approved by the Ilam University of Medical Sciences human ethics committee.

Acknowledgements

None.

References

- Houari A, Di Martino P. Effect of chlorhexidine and benzalkonium chloride on bacterial biofilm formation. Lett Appl Microbiol 2007;45: 652-6.
- [2] Neidig A, Yeung AT, Rosay T, Tettmann B, Strempel N, Rueger M, et al. TypA is involved in virulence, antimicrobial resistance and biofilm formation in *Pseudomonas aeruginosa*. BMC Microbiol 2013;13:77.
- [3] Falkinham III JO, Hilborn ED, Arduino MJ, Pruden A, Edwards MA. Epidemiology and ecology of opportunistic premise plumbing pathogens: Legionella pneumophila, Mycobacterium avium, and Pseudomonas aeruginosa. Environ Health Persp (Online) 2015;123:749.
- [4] Rasmussen BS, Christensen N, Sorensen J, Rosenvinge FS, Kolmos HJ, Skov MN. Outbreak of *Pseudomonas aeruginosa* bacteraemia in a haematology department. Danish Med J 2015;62:A5040.
- [5] Pachori P, Gothalwal R, Gandhi P. Emergence of antibiotic resistance *Pseudomonas aeruginosa* in intensive care unit; a critical review. Genes Dis 2019;6:109.
- [6] Redelman CV, Chakravarty S, Anderson GG. Antibiotic treatment of *Pseudomonas aeruginosa* biofilms stimulates expression of the magnesium transporter gene mgtE. Microbiology 2014;160:165–78.
- [7] Alhusseini LB, Maleki A, Kouhsari E, Ghafourian S, Mahmoudi M, Al Marjani MF. Evaluation of type II toxin-antitoxin systems, antibiotic resistance, and biofilm production in clinical MDR *Pseudomonas aeruginosa* isolates in Iraq. Genes Rep 2019 Dec 1;17:100546.
- [8] Tyerman JG, Ponciano JM, Joyce P, Forney LJ, Harmon LJ. The evolution of antibiotic susceptibility and resistance during the formation of *Escherichia coli* biofilms in the absence of antibiotics. BMC Evol Biol 2013;13:1.
- [9] Zaïri A, Ferrières L, Latour-Lambert P, Beloin C, Tangy F, Ghigo J-M, et al. In vitro activities of dermaseptins K4S4 and K4K20S4 against *Escherichia coli, Staphylococcus aureus,* and *Pseudomonas aeruginosa* planktonic growth and biofilm formation. Antimicrob Agents Chemother 2014;58:2221-8.
- [10] Geyik AG, Kılıç B, Çeçen F. Extracellular polymeric substances (EPS) and surface properties of activated sludges: effect of organic carbon sources. Environ Sci Poll Res 2016;23:1653–63.
- [11] Klausen M, Heydorn A, Ragas P, Lambertsen L, Aaes-Jørgensen A, Molin S, et al. Biofilm formation by *Pseudomonas aeruginosa* wild type, flagella and type IV pili mutants. Mol Microbiol 2003;48:1511-24.
- [12] Veerachamy S, Yarlagadda T, Manivasagam G, Yarlagadda PK. Bacterial adherence and biofilm formation on medical implants: a review. Proc Inst Mech Eng H: J Eng Med 2014;228:1083–99.
- [13] Mirani ZA, Jamil N. Effect of sub-lethal doses of vancomycin and oxacillin on biofilm formation by vancomycin intermediate resistant *Staphylococcus aureus*. J Basic Microbiol 2011;51:191–5.
- [14] Aparna MS, Yadav S. Biofilms: microbes and disease. Braz J Infect Dis 2008;12:526-30.
- [15] Ningthoujam DS, Shovarani N. Isolation and characterization of a Pseudomonas aeruginosa strain DN1 degrading p-nitrophenol. Res J Microbiol 2008;3:345–51.
- [16] Hengzhuang W, Ciofu O, Yang L, Wu H, Song Z, Oliver A, et al. High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in *Pseudomonas aeruginosa* biofilms. Antimicrob Agents Chemother 2013;57:196–204.
- [17] Badmasti F, Siadat SD, Bouzari S, Ajdary S, Shahcheraghi F. Molecular detection of genes related to biofilm formation in multidrug-resistant *Acinetobacter baumannii* isolated from clinical settings. J Med Microbiol 2015;64:559–64.
- [18] Perez LRR, Costa M, Freitas AL, Barth ALJ. Evaluation of biofilm production by *Pseudomonas aeruginosa* isolates recovered from cystic

fibrosis and non-cystic fibrosis patients. Braz J Microbiol 2011 Jun;42: 476–9.

- [19] Saeed Hemati NS, Ghafurian S, Maleki F, Mahdavi Z, Hassan A, Valadbeigi H, et al. The association of biofilm formation and subminimal inhibitory concentrations of antimicrobial agents. J Bas Res Med Sci 2016;3:26–30.
- [20] Tsai S-H, Lai H-C, Hu S-T. Subinhibitory doses of aminoglycoside antibiotics induce changes in the phenotype of *Mycobacterium abscessus*. Antimicrob Agents Chemother 2015;59:6161–9.
- [21] Kaplan JB, Izano EA, Gopal P, Karwacki MT, Kim S, Bose JL, et al. Low levels of β -lactam antibiotics induce extracellular DNA release and biofilm formation in *Staphylococcus aureus*. MBio 2012;3(4). e00198–12.
- [22] Aka ST, Haji SH. Sub-MIC of antibiotics induced biofilm formation of *Pseudomonas aeruginosa* in the presence of chlorhexidine. Braz J Microbiol 2015;46:149-54.
- [23] Kaplan JB. Antibiotic-induced biofilm formation. Int J Artif Organs 2011;34:737-51.
- [24] Ogunniyi TA, Oni PO, Juba A, Asaolu SO, Kolawole DO. Disinfectants/antiseptics in the management of Guinea worm ulcers in the rural areas. Acta Trop 2000;74:33–8.

- [25] Ghaneian MT, Ehrampoush MH, Jebali A, Hekmatimoghaddam S, Mahmoudi M. Antimicrobial activity, toxicity and stability of phytol as a novel surface disinfectant. Environ Health Eng Manage J 2015;2:13–6.
- [26] Greene C, Vadlamudi G, Newton D, Foxman B, Xi C. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of *Acinetobacter baumannii*. Am J Infect Contr 2016;44:e65–71.
- [27] Lefebvre E, Vighetto C, Di Martino P, Garde VL, Seyer D. Synergistic antibiofilm efficacy of various commercial antiseptics, enzymes and EDTA: a study of *Pseudomonas aeruginosa* and *Staphylococcus aureus* biofilms. Int J Antimicrob Agents 2016;48:181–8.
- [28] Laureti L, Matic I, Gutierrez A. Bacterial responses and genome instability induced by subinhibitory concentrations of antibiotics. Antibiotics 2013;2:100–14.
- [29] Ebrahimi A, Hemati M, Shabanpour Z, Dehkordi SH, Bahadoran S, Lotfalian S, et al. Effects of benzalkonium chloride on planktonic growth and biofilm formation by animal bacterial pathogens. Jundishapur J Microbiol 2015;8(2).
- [30] Jolivet-Gougeon A, Bonnaure-Mallet M. Biofilms as a mechanism of bacterial resistance. Drug Discov Today:Technol 2014;11:49-56.